Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.
Condition: Hyperlipidemias
MeSH terms: Hyperlipidemias; Hyperlipoproteinemias
Intervention: CP105F; Placebo
Intervention description: Natural Health Product; tablet manufactured to mimic the CP105F beta-glucan
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 263.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      The objective of this study is to evaluate the effects of adding beta-glucan (1.5 g, 3 g or 6
      g daily) administered three times a day (TID) in divided doses, to atorvastatin (10 mg - 20
      mg) once a day or an equivalent dose of another statin on heart disease lipid risk factors.
    

Eligibility criteria:

        Inclusion Criteria:

        Subjects must meet ALL of the following inclusion criteria in order to be eligible for this
        study:

          1. Male or female ≥18 years of age

          2. Subjects with hyperlipidemia treated with stable dose of statin for at least 6 weeks;
             either atorvastatin (10 mg to 20 mg daily) or equivalent dose of another statin at the
             time of informed consent and with LDL-C level >3.37 mmol/L (130 mg/dL) in fasting
             conditions at screening

          3. Subjects willing to maintain stable standard cholesterol lowering diet (Appendix 2)
             and physical activity level throughout the study

          4. Female of childbearing potential must have a negative urine pregnancy test at
             screening and randomization baseline Visit 2

             Women are considered not of childbearing potential if they:

               1. Have had a hysterectomy, a bilateral oophorectomy or tubal ligation prior to
                  Combination Therapy Baseline Visit.

               2. Are postmenopausal defined as no menses for at least 1 year and have a serum FSH
                  level of 40 IU/L.

             Women of childbearing potential must agree to use an effective method of birth control
             throughout the study. Acceptable means of birth control include: implantable
             contraceptives, injectable contraceptives, oral contraceptives, transdermal
             contraceptives, intrauterine devices, male or female condoms with spermicide,
             abstinence, or a sterile sexual partner

          5. Ability and willingness to give written informed consent and to comply with the
             requirements of the study

        Exclusion Criteria:

        A subject who meets any of the following criteria will NOT be eligible to the study:

          1. Use of any other lipid modifying drugs including but not limited to:

               1. Niacin (nicotinic acid) or niacinamide (nicotinamide)

               2. Fibrates or fibric acid derivatives including fenofibrate, gemfibrozil,
                  clofibrate

               3. Bile acid sequestrants including cholestyramine, colesevelam, colestipol

               4. Ezetimibe

               5. PCSK9 inhibitors

               6. Systemic corticosteroids

          2. Use of any other lipid modifying supplements within the last 30 days, including but
             not limited to (a 30-day wash out period is permitted):

               1. Beta-glucan supplements other than the investigational product

               2. Omega-3 fatty acids

               3. Supplements containing flaxseed, fish oil, or algal oil

               4. Sterol/stanol products

               5. Red yeast rice supplements or soy isoflavone supplements

               6. Dietary fiber supplements including > 2 teaspoonful of Metamucil® or psyllium
                  containing supplements per day

               7. Supplements containing oats, oatmeal and oat bran.

          3. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) with the exception of
             acetylsalicylic acid (ASA) at a concentration of up to 325 mg twice a day

          4. BMI ≥ 40 kg/m2

          5. Female who is pregnant, planning to become pregnant during the study, or breast
             feeding

          6. Subject who is not willing to keep stable the exercise level during the study

          7. History of poorly controlled diabetes within the last 3 months (HbA1C >10%)

          8. Subjects with poorly controlled blood pressure defined as a sustained mean systolic
             blood pressure 160 or <100 mmHg and/or diastolic blood pressure 100 or <60 mmHg at
             screening

          9. History of unstable angina, myocardial infarction, coronary artery bypass graft
             surgery (CABG), percutaneous coronary intervention (PCI), carotid surgery or stenting,
             cerebrovascular accident, or transient ischemic attack (TIA) within 6 months prior to
             screening

         10. History of heart failure NYHA III-IV within 12 months prior to screening.

         11. Subjects with clinically significant electrocardiographic abnormalities

         12. Subjects with history of clinically significant endocrine disease known to influence
             serum lipids

         13. Subjects with evidence of hepatic disease (ALT and/or AST greater than 2X ULN, total
             bilirubin greater than 1.5X ULN, or cirrhosis) at screening

         14. Renal dysfunction defined as glomerular filtration rate (GFR) ≤45 mL/min/1.73 m2 at
             screening

         15. Subjects who suffer from inflammatory bowel disease or irritable bowel syndrome

         16. Known allergies or intolerance to oats

         17. History of malignancy, except subjects who have been disease-free for > 3 yrs or
             resected basal or squamous cell skin carcinoma or cervical carcinoma in situ

         18. Consumption of > 14 alcoholic drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5
             oz hard liquor at screening). Counseling should be given to encourage the subject to
             maintain consumption at or below this level throughout the study

         19. History of drug abuse

         20. Participation in another clinical trial within 30 days of signing the Information and
             Consent Form (ICF)

         21. Any condition or therapy that the investigator believes might pose a risk to the
             subject or makes participation in the study not in the subject's best interest